Zurich Cantonal Bank
RARE icon

Zurich Cantonal Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Zurich Cantonal Bank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Hold
39,894
– – ﹤0.01% 1367
2026
Q1 		$836K Buy
39,894
+11,654
+41% +$262K ﹤0.01% 1539
2025
Q4 		$650K Buy
28,240
+1,875
+7% +$61.7K ﹤0.01% 1615
2025
Q3 		$793K Sell
26,365
-14
-0.1% -$420 ﹤0.01% 1442
2025
Q2 		$959K Buy
26,379
+4,027
+18% +$145K ﹤0.01% 1245
2025
Q1 		$809K Sell
22,352
-522
-2% -$21.7K ﹤0.01% 1292
2024
Q4 		$962K Buy
22,874
+5,104
+29% +$253K ﹤0.01% 1199
2024
Q3 		$987K Sell
17,770
-7
-0% -$357 ﹤0.01% 1132
2024
Q2 		$731K Buy
17,777
+93
+0.5% +$3.97K ﹤0.01% 1238
2024
Q1 		$826K Buy
17,684
+1,537
+10% +$72.5K ﹤0.01% 1168
2023
Q4 		$772K Buy
16,147
+2,011
+14% +$78K ﹤0.01% 1213
2023
Q3 		$504K Buy
14,136
+2,292
+19% +$90.8K ﹤0.01% 1399
2023
Q2 		$546K Buy
11,844
+947
+9% +$43.9K ﹤0.01% 1296
2023
Q1 		$437K Buy
10,897
+918
+9% +$39.4K ﹤0.01% 1374
2022
Q4 		$462K Buy
9,979
+425
+4% +$16.7K ﹤0.01% 1296
2022
Q3 		$396K Buy
9,554
+1,097
+13% +$56.4K ﹤0.01% 1342
2022
Q2 		$505K Sell
8,457
-790
-9% -$48.6K ﹤0.01% 1222
2022
Q1 		$672K Sell
9,247
-984
-10% -$68.5K ﹤0.01% 1156
2021
Q4 		$860K Buy
10,231
+3,175
+45% +$258K ﹤0.01% 1082
2021
Q3 		$636K Buy
7,056
+14
+0.2% +$1.26K ﹤0.01% 1138
2021
Q2 		$671K Sell
7,042
-353
-5% -$36.8K ﹤0.01% 1056
2021
Q1 		$842K Buy
7,395
+440
+6% +$59.9K 0.01% 941
2020
Q4 		$963K Buy
6,955
+832
+14% +$98.7K 0.01% 970
2020
Q3 		$503K Hold
6,123
– – ﹤0.01% 1094
2020
Q2 		$479K Buy
6,123
+1,296
+27% +$85.8K ﹤0.01% 1026
2020
Q1 		$214K Buy
4,827
+1,502
+45% +$78K ﹤0.01% 1202
2019
Q4 		$142K Hold
3,325
– – ﹤0.01% 1515
2019
Q3 		$142K Hold
3,325
– – ﹤0.01% 1430
2019
Q2 		$211K Buy
3,325
+212
+7% +$13.5K ﹤0.01% 1208
2019
Q1 		$216K Buy
3,113
+242
+8% +$13.8K ﹤0.01% 1163
2018
Q4 		$125K Hold
2,871
– – ﹤0.01% 1468
2018
Q3 		$219K Buy
2,871
+483
+20% +$39.3K ﹤0.01% 1253
2018
Q2 		$184K Hold
2,388
– – ﹤0.01% 1283
2018
Q1 		$122K Hold
2,388
– – ﹤0.01% 1490
2017
Q4 		$111K Buy
2,388
+880
+58% +$43.1K ﹤0.01% 1511
2017
Q3 		$80K Hold
1,508
– – ﹤0.01% 1521
2017
Q2 		$94K Sell
1,508
-840
-36% -$50.6K ﹤0.01% 1402
2017
Q1 		$159K Hold
2,348
– – ﹤0.01% 1084
2016
Q4 		$165K Buy
2,348
+922
+65% +$65.4K ﹤0.01% 1042
2016
Q3 		$101K Buy
1,426
+600
+73% +$38.3K ﹤0.01% 1257
2016
Q2 		$40K Hold
826
– – ﹤0.01% 1609
2016
Q1 		$52K Hold
826
– – ﹤0.01% 1417
2015
Q4 		$93K Buy
826
+601
+267% +$60.1K ﹤0.01% 1161
2015
Q3 		$22K Buy
225
+125
+125% +$14.3K ﹤0.01% 1470
2015
Q2 		$10K Hold
100
– – ﹤0.01% 1391
2015
Q1 		$6K Buy
+100
New +$5.55K ﹤0.01% 1758

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Zurich Cantonal Bank's RARE Position: Q2 2026 in Review

Zurich Cantonal Bank held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 39,894 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Zurich Cantonal Bank first reported a position in RARE in Q1 2015 and has held it in 46 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Zurich Cantonal Bank held 39,894 shares of Ultragenyx Pharmaceutical worth $1.33M as of Q2 2026.
  • Zurich Cantonal Bank left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1367 holding.
  • Zurich Cantonal Bank first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 46 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.